The Second Affiliated Hospital of the Army Medical University
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mo, Xiaodong
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

Recruiting
3
182
RoW
Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Graft-versus-host Disease
10/29
12/30
ABSK021-201, NCT06186804: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

Enrolling by invitation
2
64
RoW
ABSK021
Abbisko Therapeutics Co, Ltd
cGvHD
10/26
12/26
NCT06149390: ASCT Versus Chemotherapy as First-Line Consolidation Therapy inT-Cell Lymphoma

Completed
N/A
347
NA
consolidation with ASCT, consoliation therapy
Huazhong University of Science and Technology, Peking University People's Hospital, Ruijin Hospital, West China Hospital
T-cell Lymphoma Adults
01/22
07/23
NCT06301425: MRD Response-adapted Allo-HSCT for Adverse-risk AML

Recruiting
N/A
178
RoW
Intervention group, Control group
Peking University People's Hospital, Ruijin Hospital, Wuhan TongJi Hospital, Anhui Provincial Hospital
Acute Myeloid Leukemia
05/27
05/28
NCT06671717: Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma

Not yet recruiting
N/A
25
RoW
Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation
Peking University People's Hospital, Ruijin Hospital, Wuhan TongJi Hospital, West China Hospital
Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
04/27
07/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mo, Xiaodong
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

Recruiting
3
182
RoW
Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Graft-versus-host Disease
10/29
12/30
ABSK021-201, NCT06186804: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

Enrolling by invitation
2
64
RoW
ABSK021
Abbisko Therapeutics Co, Ltd
cGvHD
10/26
12/26
NCT06149390: ASCT Versus Chemotherapy as First-Line Consolidation Therapy inT-Cell Lymphoma

Completed
N/A
347
NA
consolidation with ASCT, consoliation therapy
Huazhong University of Science and Technology, Peking University People's Hospital, Ruijin Hospital, West China Hospital
T-cell Lymphoma Adults
01/22
07/23
NCT06301425: MRD Response-adapted Allo-HSCT for Adverse-risk AML

Recruiting
N/A
178
RoW
Intervention group, Control group
Peking University People's Hospital, Ruijin Hospital, Wuhan TongJi Hospital, Anhui Provincial Hospital
Acute Myeloid Leukemia
05/27
05/28
NCT06671717: Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma

Not yet recruiting
N/A
25
RoW
Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation
Peking University People's Hospital, Ruijin Hospital, Wuhan TongJi Hospital, West China Hospital
Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
04/27
07/27

Download Options